Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and ...

The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

A new discovery by the Cold Spring Harbor Laboratory could help point toward the first effective therapy for triple-negative breast cancer. Triple-negative breast cancer accounts for 10 to 15% of all ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

All patients will also receive standard doses of darolutamide. Phase 2 Clinical Trial in HER2+ Metastatic Breast Cancer In this investigator-sponsored Phase 2 clinical trial, 44 patients with ...

The report provides a detailed analysis of the current breast cancer marketed drugs and late-stage pipeline drugs. BROOKLYN, ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...